Fox Chase Cancer Center News

New research from Fox Chase Cancer Center confirms that preoperative radiation therapy does not reduce surgical complexity, reinforcing evidence that most patients benefit from proceeding directly to surgery.

New research from Fox Chase Cancer Center reveals a natural “safety switch” that allows liver cells to pause growth during injury, helping protect against cancer while the liver heals and pointing to potential new treatments for chronic liver disease.

Fox Chase Cancer Center and Omniscope, a leader in advanced molecular profiling technology announced a new research collaboration aimed at identifying novel biomarkers for immune checkpoint inhibitor (ICI) response in non-small cell lung cancer.

Fox Chase Cancer Center and Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that they have entered into a new partnership to bring advanced diagnostics based on analysis of the three-dimensional structure of DNA into broad clinical practice.

New research reveals that the oncogene ERG initiates prostate cancer by reprogramming basal cells into luminal tumor cells, uncovering early vulnerabilities that could lead to more effective treatment and prevention strategies.

A new type of treatment called tumor-infiltrating lymphocyte (TIL) therapy is offering patients with melanoma more hope and another chance.

A Fox Chase Cancer Center study found that outpatient observation cut hospital stays dramatically, with no adverse safety events reported. It also freed up inpatient beds and cut healthcare costs.

A Fox Chase Cancer Center study found that measuring a patient’s absolute lymphocyte count can predict how well they’ll respond to the therapy for non-Hodgkin lymphoma. It could offer a practical tool for guiding treatment decisions.